Acute myeloid leukemia (AML) patients usually exhibit suboptimal responses after receiving single target drug therapy.
Simultaneously targeting multiple oncogenic pathways is a promising strategy for cancer treatment.
Herein, based on the synergistic antiproliferative capacity of the PIM inhibitor
